| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,214 |
12,420 |
$1.36M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,608 |
6,431 |
$503K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,934 |
4,921 |
$459K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,796 |
2,795 |
$405K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
9,491 |
9,227 |
$349K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
9,441 |
9,232 |
$266K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,928 |
3,878 |
$57K |
| 87430 |
|
2,854 |
2,783 |
$42K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
995 |
943 |
$41K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,974 |
1,886 |
$30K |
| 99051 |
|
1,866 |
1,817 |
$12K |
| 87807 |
|
388 |
383 |
$4K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
29 |
29 |
$1K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
78 |
78 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
810 |
780 |
$957.33 |
| 90756 |
|
74 |
74 |
$860.75 |
| 87428 |
|
13 |
13 |
$382.07 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
12 |
12 |
$19.20 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
12 |
12 |
$18.44 |